⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7377614 | 1.00 | L3MBTL1 (0.42) | — | |
| Hydrochloric Acid SCHEMBL2169126 | 0.97 | — | — | |
| Bromide SCHEMBL28198911 | 0.94 | L3MBTL1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL1451885 | 0.94 | LMNA (0.40) | — | |
| Hydrochloric Acid SCHEMBL29666323 | 0.81 | — | — | |
| SCHEMBL312822 | 0.80 | TSHR (0.39) | — | |
| SCHEMBL2746571 | 0.78 | — | — | |
| SCHEMBL29185897 | 0.78 | TSHR (0.37) | — | |
| SCHEMBL20901908 | 0.78 | — | — | |
| SCHEMBL2996071 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118865-A | Preparation method of organic intermediate N' - (2, 4-dichloro-5-isopropoxyphenyl) pivaloyl hydrazide | 中国科学技术大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118184492-A | Synthesis method and synthetic application of intermediate 2, 4-dichloro-5-bromoisopropoxy benzene | 中国科学技术大学 | 2024-06-14 | — | — | CN | claimed |
| CN-117843523-A | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117466769-A | Preparation method of organic intermediate N' - (2, 4-dichloro-5-isopropoxyphenyl) pivaloyl hydrazide | 中国科学技术大学 | 2024-01-30 | — | — | CN | claimed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | claimed |
| CN-111303064-A | Synthetic method of furazolidone metabolite AOZ | 中国农业科学院农业质量标准与检测技术研究所 | 2020-06-19 | — | — | CN | claimed |
| US-20160081332-A1 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | AKZO NOBEL CHEMICALS INT BV (NL) | 2016-03-24 | — | — | US | claimed |
| EP-2648524-A2 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | Akzo Nobel Chemicals International B.V. (NL) | 2013-10-16 | — | — | EP | claimed |
| WO-2012076567-A2 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2012-06-14 | — | — | WO | claimed |
| CN-1161128-C | Angiogenic inhibitory compounds | О | 2004-08-11 | — | — | CN | claimed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | claimed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | claimed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | claimed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | claimed |
| CN-1052717-C | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 2000-05-24 | — | — | CN | claimed |
| EP-0653419-B1 | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1997-09-17 | — | — | EP | claimed |
| CN-1108242-A | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1995-09-13 | — | — | CN | claimed |
| EP-0653419-A1 | Preparation of pivaloyl hydrazide | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-05-17 | — | — | EP | claimed |
| JP-7215924-A | — | — | None | — | — | JP | disclosed |
| JP-7215924-A | — | — | None | — | — | JP | disclosed |
| CN-121537309-A | Method for preparing trimethyl acethydrazide | 安徽广信成辰科技有限公司 | 2026-02-17 | — | — | CN | disclosed |
| CN-121537309-A | Method for preparing trimethyl acethydrazide | 安徽广信成辰科技有限公司 | 2026-02-17 | — | — | CN | disclosed |
| EP-4682145-A1 | BENZOHETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Cascade Pharmaceuticals, Inc. (CN) | 2026-01-21 | — | — | EP | disclosed |
| CN-117843523-B | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2026-01-13 | — | — | CN | disclosed |
| CN-117843523-B | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2026-01-13 | — | — | CN | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-3789395-B1 | PEGYLATION OF FGF21 | BRISTOL MYERS SQUIBB CO (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4545553-A2 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | ShangPharma Innovation Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025062334-A1 | 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZENESULFONAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER | BEIGENE SWITZERLAND GMBH (CH) | 2025-03-27 | — | — | WO | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2025-02-25 | — | — | US | disclosed |
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250034101-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| WO-2025007853-A1 | 2-INDOLINONE COMPOUND SERVING AS VEGFR AND PKA DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 远森制药（杭州）有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-3663291-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-119118865-A | Preparation method of organic intermediate N' - (2, 4-dichloro-5-isopropoxyphenyl) pivaloyl hydrazide | 中国科学技术大学 | 2024-12-13 | — | — | CN | disclosed |
| US-12145914-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-11-19 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| CN-113677659-B | Substituted amide compounds useful as farnesoid X receptor modulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240224781-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| EP-4392998-A1 | ELECTRICALLY CONDUCTIVE ADHESIVE COMPOSITION FOR BONDING SOLAR CELLS | Henkel AG & Co. KGaA (DE) | 2024-07-03 | — | — | EP | disclosed |
| CN-116813569-B | Preparation method of anticancer drug intermediate and preparation method of anticancer drug | 衡阳市中心医院 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024133200-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389746-A2 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2024-06-26 | — | — | EP | disclosed |
| CN-114213333-B | Thiol compound, method for synthesizing same, and use of thiol compound | 四国化成工业株式会社 | 2024-06-25 | — | — | CN | disclosed |
| CN-118184492-A | Synthesis method and synthetic application of intermediate 2, 4-dichloro-5-bromoisopropoxy benzene | 中国科学技术大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| US-11999732-B2 | P2X3 receptor antagonists | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2024-06-04 | — | — | US | disclosed |
| CN-118063518-A | Organic electroluminescent material and device | 环球展览公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11981753-B2 | Peptide compound and application thereof, and composition containing peptide compound | SHANGPHARMA INNOVATION INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-117957068-A | Method for discharging resin composition, method for manufacturing electronic component, and electronic component | 纳美仕有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117957270-A | Resin composition for injection dispensing, adhesive for electronic component, cured product thereof, and electronic component | 纳美仕有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117940488-A | Resin composition, adhesive for electronic component, cured product thereof, and electronic component | 纳美仕有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117859183-A | Conductive adhesive composition for bonding solar cells | 汉高股份有限及两合公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843523-A | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843523-A | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843523-A | Preparation method of trimethyl acethydrazide | 安徽广信农化股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240109910-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND / OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| EP-4341354-A1 | CURABLE COMPOSITION AND USE THEREOF | Henkel AG & Co. KGaA (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-3483207-B1 | SHEET | OJI HOLDINGS CORP (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117651730-A | Resin composition and adhesive | 纳美仕有限公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024033389-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117466769-A | Preparation method of organic intermediate N' - (2, 4-dichloro-5-isopropoxyphenyl) pivaloyl hydrazide | 中国科学技术大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-117466769-A | Preparation method of organic intermediate N' - (2, 4-dichloro-5-isopropoxyphenyl) pivaloyl hydrazide | 中国科学技术大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-112584898-B | P2X 3 Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4301823-A1 | CURABLE ADHESIVE COMPOSITION COMPRISING MALEIMIDE AND THIOL | Henkel AG & Co. KGaA (DE) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377731-A | Curable composition and use thereof | 汉高股份有限及两合公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023218702-A1 | CURING AGENT AND USE THEREOF | 四国化成工業株式会社 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218862-A1 | THIOL COMPOUND AND USES THEREOF | 四国化成工業株式会社 | 2023-11-16 | — | — | WO | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116940647-A | Curable adhesive composition comprising maleimide and thiol | 汉高股份有限及两合公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230322976-A1 | METHOD OF EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD OF PRODUCING COMPOSITE BODY | BIODYNAMIC RESEARCH FOUNDATION (JP) | 2023-10-12 | — | — | US | disclosed |
| US-11780963-B2 | Multi-arm multi-claw polyethylene glycol derivative suitable for click chemistry reactions | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2023-10-10 | — | — | US | disclosed |
| CN-116813569-A | Preparation method of anticancer drug intermediate and preparation method of anticancer drug | 衡阳市中心医院 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11759528-B2 | Peg linker and ligand drug conjugate | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2023-09-19 | — | — | US | disclosed |
| CN-116751174-A | Synthesis method of aryl substituted 1,3, 4-oxadiazole derivative | 铜陵欣诺科新材料有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230265080-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMA (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265197-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| CN-112823176-B | resin composition | 纳美仕有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| CN-112823177-B | Resin composition | 纳美仕有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| CN-111788247-B | Coated particles | 味之素株式会社 | 2023-07-18 | — | — | CN | disclosed |
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-4190824-A1 | METHOD FOR EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD FOR PRODUCING COMPOSITE BODY | Toray Industries, Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230150955-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-06 | — | — | US | disclosed |
| CN-115819494-A | Additive system for protein pegylation | 百时美施贵宝公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11603358-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-03-14 | — | — | US | disclosed |
| WO-2023024071-A1 | ELECTRICALLY CONDUCTIVE ADHESIVE COMPOSITION FOR BONDING SOLAR CELLS | HENKEL AG & CO. KGAA (DE) | 2023-03-02 | — | — | WO | disclosed |
| CN-108350025-B | Additive system for protein pegylation | 百时美施贵宝公司 | 2023-02-21 | — | — | CN | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230002967-A1 | TEXTILE PRINTING INK | Konica Minolta, Inc. (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-111315719-B | Thiol compound, method for synthesizing same, and use of thiol compound | 四国化成工业株式会社 | 2022-12-27 | — | — | CN | disclosed |
| CN-108602762-B | Linker molecules and their use in methods for purifying peptides | 贝兰迪克有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| US-11518812-B2 | Monoclonal antibodies against HER2 epitope and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| CN-112840004-B | Resin composition | 纳美仕有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220323595-A1 | SUSTAINED DELIVERY OF ANGIOPOETIN-LIKE 3 POLYPEPTIDES | NOVARTIS AG (CH) | 2022-10-13 | — | — | US | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115124813-A | Resin composition | 味之素株式会社 | 2022-09-30 | — | — | CN | disclosed |
| CN-115089586-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11447612-B2 | Sheet | Oji Holdings Corporation (JP) | 2022-09-20 | — | — | US | disclosed |
| WO-2022183481-A1 | CURABLE ADHESIVE COMPOSITION COMPRISING MALEIMIDE AND THIOL | HENKEL AG & CO. KGAA (DE) | 2022-09-09 | — | — | WO | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022175514-A1 | N-(PYRIDIN-2-YL)-ACETAMIDES AS P2X3 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |
| US-20220242908-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-04 | — | — | US | disclosed |
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-108794427-B | Synthetic method of 1,3, 4-thiadiazole derivative | 江苏快达农化股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220235062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-28 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-112566902-B | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220160883-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220160883-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-110431168-B | Curable composition and structure | 味之素株式会社 | 2022-04-29 | — | — | CN | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| CN-114276298-A | Thiol compound, method for synthesizing same, and use of thiol compound | 四国化成工业株式会社 | 2022-04-05 | — | — | CN | disclosed |
| CN-114213333-A | Thiol compound, method for synthesizing same, and use of thiol compound | 四国化成工业株式会社 | 2022-03-22 | — | — | CN | disclosed |
| EP-3953360-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022025228-A1 | METHOD FOR EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD FOR PRODUCING COMPOSITE BODY | 東レ株式会社 | 2022-02-03 | — | — | WO | disclosed |
| US-20220024886-A1 | COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11213589-B2 | Additive systems for use in protein PEGylation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3924337-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924329-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210386867-A1 | FILTERABLE DUOCARMYCIN-CONTAINING ANTIBODY-DRUG CONJUGATE COMPOSITIONS AND RELATED METHODS | BYONDIS B.V. (NL) | 2021-12-16 | — | — | US | disclosed |
| CN-113767105-A | Heterocyclic compounds as inhibitors of monoacylglycerol lipases (MAGL) | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113677666-A | Substituted bicyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113677659-A | Substituted amide compounds useful as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3910014-A1 | POLYACETAL RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-109476856-B | Sheet material | 王子控股株式会社 | 2021-11-09 | — | — | CN | disclosed |
| US-20210317113-A1 | 1,2,3-TRIAZOLE DERIVATIVES AND USES THEREOF | Alxerion Biotech LLC | 2021-10-14 | — | — | US | disclosed |
| US-20210301095-A1 | SHEET | Oji Holdings Corporation (JP) | 2021-09-30 | — | — | US | disclosed |
| CN-113444340-A | Resin composition | 味之素株式会社 | 2021-09-28 | — | — | CN | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| CN-109715695-B | Resin composition, adhesive, sealing material, dam agent, semiconductor device, and image sensor module | 纳美仕有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-106967208-B | Coated particles | 味之素株式会社 | 2021-09-10 | — | — | CN | disclosed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210251968-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2021-08-19 | — | — | US | disclosed |
| CN-113272285-A | Oxadiazole-containing compound and pharmaceutical composition containing the same | 爱思开生物制药株式会社 | 2021-08-17 | — | — | CN | disclosed |
| CN-113272274-A | Thiol compound, synthesis method thereof and application of thiol compound | 四国化成工业株式会社 | 2021-08-17 | — | — | CN | disclosed |
| US-20210246139-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2021-08-12 | — | — | US | disclosed |
| EP-3854788-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2021-07-28 | — | — | EP | disclosed |
| US-11053208-B2 | Compound having oxadiazole and pharmaceutical composition containing the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-11053185-B2 | Dendritic polyethylene glycol derivative, and preparation method and application thereof | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2021-07-06 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-20210179587-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2021-06-17 | — | — | US | disclosed |
| CN-112840004-A | Resin composition | 纳美仕有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3820566-A1 | P2X3 RECEPTOR ANTAGONISTS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2021-05-19 | — | — | EP | disclosed |
| CN-112823177-A | Resin composition | 纳美仕有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112823176-A | Resin composition | 纳美仕有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20210138077-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2021-05-13 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| CN-112745793-A | Curable composition | 味之素株式会社 | 2021-05-04 | — | — | CN | disclosed |
| CN-112745770-A | Curable composition | 味之素株式会社 | 2021-05-04 | — | — | CN | disclosed |
| EP-3812372-A2 | 7-HETEROCYCLYL SUBSTITUTED SANCYCLINE DERIVATIVES FOR TREATING BACTERIAL, VIRAL AND PARASITIC INFECTIONS (E.G. MALARIA) OR INFLAMMATORY DISEASES | Paratek Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210115001-A1 | Compound Having Oxadiazole And Pharmaceutical Composition Containing The Same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-04-22 | — | — | US | disclosed |
| WO-2021069671-A1 | HEXAHYDRO-5,8-EPOXYCYCLOHEPTA[c]PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE CB1 AND/OR CB2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-15 | — | — | WO | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-3802501-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW Laboratories Inc. (KY) | 2021-04-14 | — | — | EP | disclosed |
| EP-2935311-B1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112584898-A | P2X3Receptor antagonists | 瑞蔻达蒂化学和制药工业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112566902-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| CN-110372634-B | Method for synthesizing 2-methylamino-5-tert-butyl-1, 3, 4-thiadiazole | 宁夏常晟药业有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10947317-B2 | NaPi2b-targeted antibody-drug conjugates and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3789395-A1 | PEGYLATION OF FGF21 | Bristol-Myers Squibb Company (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3789395-A1 | PEGYLATION OF FGF21 | Bristol-Myers Squibb Company (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2021032727-A1 | METHOD FOR COVERING ELONGATED ARTICLES, IN PARTICULAR LINES | TESA SE (DE) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032822-A1 | METHOD FOR COVERING ELONGATED ARTICLES, IN PARTICULAR LINES | TESA SE (DE) | 2021-02-25 | — | — | WO | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925859-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| CN-112279808-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-29 | — | — | CN | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20210008099-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEATTLE GENETICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10870624-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| CN-107011514-B | Photoand thermosetting resin composition | 味之素株式会社 | 2020-12-18 | — | — | CN | disclosed |
| US-20200376129-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200361939-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED. | 2020-11-19 | — | — | US | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-111902511-A | Sealing adhesive | 味之素株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-10815194-B2 | Process for the preparation of mono-protected α,ω-diamino alkanes | BYONDIS B.V. (NL) | 2020-10-27 | — | — | US | disclosed |
| CN-111788247-A | Coated particles | 味之素株式会社 | 2020-10-16 | — | — | CN | disclosed |
| WO-2020207941-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| US-20200316062-A1 | COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3714001-A1 | PROCESS FOR PRODUCING PRESSURE-SENSITIVE REACTIVE ADHESIVE TAPES | TESA SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3713984-A1 | ADHESIVE TAPES BASED ON EPOXY RESIN REACTIVE ADHESIVES | TESA SE (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200276319-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3380487-B1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3380487-B1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL MYERS SQUIBB CO (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10751417-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2020-08-25 | — | — | US | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168152-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-3203840-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10722497-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10722497-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200230110-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200230110-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| CN-111303064-A | Synthetic method of furazolidone metabolite AOZ | 中国农业科学院农业质量标准与检测技术研究所 | 2020-06-19 | — | — | CN | disclosed |
| EP-3663291-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Biogen MA Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3663291-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Biogen MA Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10676467-B2 | Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3650464-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-20200140611-A1 | MULTI-ARM MULTI-CLAW POLYETHYLENE GLYCOL DERIVATIVE SUITABLE FOR CLICK CHEMISTRY REACTIONS | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200131107-A1 | DENDRITIC POLYETHYLENE GLYCOL DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOF | JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) | 2020-04-30 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
| US-10617677-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617765-B2 | Additive systems for use in protein PEGylation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| WO-2020060299-A1 | COMPOUND CONTAINING OXADIAZOLE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이바이오팜 주식회사 | 2020-03-26 | — | — | WO | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3000608-B1 | THERMOSENSITIVE RECORDING MEDIUM | OJI HOLDINGS CORP (JP) | 2020-03-18 | — | — | EP | disclosed |
| EP-3404027-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-2800745-B1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORY, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| US-20200038373-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2020-02-06 | — | — | US | disclosed |
| US-20200038373-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2020-02-06 | — | — | US | disclosed |
| US-20200031941-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| CN-107431025-B | Heat-curable sealant composition and use thereof | 汉高股份有限及两合公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2020011921-A1 | P2X3 RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2020-01-16 | — | — | WO | disclosed |
| CN-107428781-B | Mercapto ethyl glycoluril compound and application thereof | 四国化成工业株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2019232724-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019232724-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233447-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233447-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
| CN-110505874-A | Molecule and relative intermediate, composition and method with desinsection effectiveness | DOW AGROSCIENCES LLC | 2019-11-26 | — | — | CN | disclosed |
| US-20190351065-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-11-21 | — | — | US | disclosed |
| US-20190351065-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-11-21 | — | — | US | disclosed |
| WO-2019181789-A1 | SEALING ADHESIVE | 味の素株式会社 | 2019-09-26 | — | — | WO | disclosed |
| CN-110214136-A | Pyrazole derivatives as MALT1 inhibitor | 詹森药业有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190248803-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10335393-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10335393-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2019-07-02 | — | — | US | disclosed |
| CN-109963837-A | 2-aminothioformyl-2- (3- (5- (4-cyanophenoxy) pyridin-2-yl) -2- (2, 4-difluorophenyl) -3, 3-difluoro-2-hydroxypropyl) hydrazine-l-tert-butyl formate and preparation method thereof | 美国陶氏益农公司 | 2019-07-02 | — | — | CN | disclosed |
| US-10323061-B2 | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323061-B2 | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10308659-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190160181-A1 | COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPY | MERSANA THERAPEUTICS, INC. | 2019-05-30 | — | — | US | disclosed |
| EP-3483207-A1 | SHEET | Oji Holdings Corporation (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3483208-A1 | SHEET | Oji Holdings Corporation (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-10286090-B2 | Targeted contrast agents comprising a hydrazide functional group | RF THERAPEUTICS INC. (CA) | 2019-05-14 | — | — | US | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190117790-A1 | PEG LINKER AND LIGAND DRUG CONJUGATE | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2019-04-25 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10240074-B2 | Degradable and recyclable epoxy conductive adhesive as well as preparing, degrading and recycling methods therefor | SHENGYI TECHNOLOGY CO., LTD. (CN) | 2019-03-26 | — | — | US | disclosed |
| US-10226535-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190008833-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2019-01-10 | — | — | US | disclosed |
| US-20190002450-A1 | COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (S1P1), IMAGING OF S1P1, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| CN-109071549-A | 1,5- dihydro -4H- pyrazolo [3,4-d] pyrimidin-4-one and 1,5- dihydro -4H- pyrazolo [4,3-c] pyridine -4- ketone as PDE1 inhibitor | H.隆德贝克有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108884068-A | 1- cyano-pyrolidin derivative as DUB inhibitor | 特殊治疗有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-3404027-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Biogen MA Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| CN-108794427-A | A kind of synthetic method of 1,3,4- thiadiazoles derivatives | 江苏快达农化股份有限公司 | 2018-11-13 | — | — | CN | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-20180305359-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2018-10-25 | — | — | US | disclosed |
| US-20180289675-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| EP-3380487-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | Bristol-Myers Squibb Company (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10058535-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-2858991-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2858991-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | BIOGEN MA INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-108350025-A | additive system for protein PEGylation | 百时美施贵宝公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-105121436-B | New pyridine derivate | 豪夫迈·罗氏有限公司 | 2018-07-27 | — | — | CN | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-20180200225-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-07-19 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170876-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| CN-108137566-A | Triazole derivative | 豪夫迈·罗氏有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| CN-106336385-B | The synthetic method of Yi Zhong Evil humulones | 江苏丰华化学工业有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9901567-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2018-02-27 | — | — | US | disclosed |
| US-9901567-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2018-02-27 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9862685-B2 | Histone deacetylase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-01-09 | — | — | US | disclosed |
| US-9861614-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9861614-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2978755-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| CN-105555783-B | Include the autotaxin inhibitors of heteroaromatic rings benzyl amide ring core | 诺华股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170342301-A1 | Degradable and Recyclable Epoxy Conductive Adhesive as well as Preparing, Degrading and Recycling Methods therefor | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9815851-B2 | Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20170319551-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2017-11-09 | — | — | US | disclosed |
| US-20170319551-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2017-11-09 | — | — | US | disclosed |
| US-20170319551-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2017-11-09 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170313698-A1 | POLYHETEROARL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-20170313698-A1 | POLYHETEROARL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313778-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-9789721-B2 | Thermosensitive recording medium | Oji Holdings Corporation (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170266311-A1 | NaPi2b-targeted Antibody-Drug Conjugates and Methods of Use Thereof | MERSANA THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| EP-3215505-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2017147174-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147174-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240587-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240587-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240587-A1 | HETEROARYL CONTAINING BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170231953-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | CLEVELAND CLINIC FOUND (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-3203840-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9676765-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-9676765-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| WO-2017091568-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091568-A1 | ADDITIVE SYSTEMS FOR USE IN PROTEIN PEGYLATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-01 | — | — | WO | disclosed |
| US-9656957-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| CN-105073746-B | Substituted imidazopyridines as HDM2 inhibitors | 默沙东公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9598355-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9585874-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585874-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585874-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170029514-A1 | ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | IMMUNOGEN, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-2852590-B1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9556351-B2 | Rubber composition suitable for use as a cap ply in a tire | Bridgestone Americas Tire Operations, Inc. (US) | 2017-01-31 | — | — | US | disclosed |
| CN-104507940-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| CN-106336385-A | Oxadiazon synthesis method | 江苏丰华化学工业有限公司 | 2017-01-18 | — | — | CN | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-9520574-B2 | Electroluminescent devices based on phosphorescent iridium and related group VIII metal multicyclic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-13 | — | — | US | disclosed |
| US-9520574-B2 | Electroluminescent devices based on phosphorescent iridium and related group VIII metal multicyclic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-13 | — | — | US | disclosed |
| US-9520574-B2 | Electroluminescent devices based on phosphorescent iridium and related group VIII metal multicyclic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-12-13 | — | — | US | disclosed |
| US-20160354347-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-12-08 | — | — | US | disclosed |
| US-20160355480-A1 | SUBSTITUTED PYRIDINES AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2016-12-08 | — | — | US | disclosed |
| US-20160354347-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-12-08 | — | — | US | disclosed |
| US-20160354347-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-12-08 | — | — | US | disclosed |
| EP-3099682-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160326194-A1 | IONIC LIQUID SUPPORTED ORGANOTIN REAGENTS FOR THE MANUFACTURING OF RADIOPHARMACEUTICALS COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-11-10 | — | — | US | disclosed |
| CN-106084714-A | A kind of agricultural mulching and preparation method thereof | 吉林省农业科学院 | 2016-11-09 | — | — | CN | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2016-10-13 | — | — | US | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| CN-105968236-A | Novel emulgator for emulsified explosive and preparation method of novel emulgator | 中国葛洲坝集团易普力股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-104395309-B | Cyclic bridgehead ether DGAT1 inhibitors | 诺华股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-3045449-A1 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | Paratek Pharmaceuticals, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9393239-B2 | Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-07-19 | — | — | US | disclosed |
| US-9393239-B2 | Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-07-19 | — | — | US | disclosed |
| US-9393239-B2 | Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-07-19 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160145246-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-05-26 | — | — | US | disclosed |
| US-20160145246-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-05-26 | — | — | US | disclosed |
| US-20160145246-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2016-05-26 | — | — | US | disclosed |
| WO-2016074184-A1 | THERMALLY CURABLE SEALANT COMPOSITION AND USE THEREOF | ABLESTIK (SHANGHAI) LTD. (CN) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| CN-103917528-B | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-04-20 | — | — | CN | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016050210-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050208-A1 | BIO-RELATED SUBSTANCE MODIFIED BY MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096804-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| EP-3000608-A1 | THERMOSENSITIVE RECORDING MEDIUM | Oji Holdings Corporation (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-20160081332-A1 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | AKZO NOBEL CHEMICALS INT BV (NL) | 2016-03-24 | — | — | US | disclosed |
| US-20160082760-A1 | THERMOSENSITIVE RECORDING MEDIUM | Oji Holdings Corporation (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| CN-105419605-A | Environment-friendly odorless furniture and preparation method thereof | SHANGHAI TAOHONG CHEMICAL TECH CO LTD | 2016-03-23 | — | — | CN | disclosed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
| EP-2748151-B1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2748151-B1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-16 | — | — | EP | disclosed |
| CN-103221409-B | Herbicidal benzoxazinones | BASF SE (DE) | 2016-03-09 | — | — | CN | disclosed |
| CN-105385331-A | Environment-friendly odorless furniture and manufacturing method thereof | SICHUAN NUKE HOUSEHOLD CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-9266843-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266843-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266843-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160046561-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160040024-A1 | RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC | 2016-02-11 | — | — | US | disclosed |
| EP-2980088-A1 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2978755-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20160016968-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9232787-B2 | Viscoelastic surfactant as drift control agent in pesticide formulations | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2016-01-12 | — | — | US | disclosed |
| US-20150361074-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| CN-103339111-B | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG (CH) | 2015-12-16 | — | — | CN | disclosed |
| CN-105121436-A | Novel pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-02 | — | — | CN | disclosed |
| US-9201001-B2 | Visual detection of fluoride ions | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) | 2015-12-01 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150313874-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-11-05 | — | — | US | disclosed |
| EP-2931723-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND -LACTAMASE INHIBITORS | Fedora Pharmaceuticals Inc. (CA) | 2015-10-21 | — | — | EP | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| US-9163127-B2 | Rubber composition suitable for use as a cap ply in a tire | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2015-10-20 | — | — | US | disclosed |
| CN-103408454-B | A kind of preparation method of hydrazide kind compound | LANZHOU UNIVERSITY (CN) | 2015-09-23 | — | — | CN | disclosed |
| EP-2132178-B1 | JNK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015113920-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | disclosed |
| US-20150216844-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2015-08-06 | — | — | US | disclosed |
| US-9096543-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096543-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096543-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9079854-B2 | Hydrazone modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-07-14 | — | — | US | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9062059-B2 | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062059-B2 | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166563-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2015-04-23 | — | — | US | disclosed |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2015-04-23 | — | — | US | disclosed |
| US-20150111893-A1 | Nuclear Transport Modulators and Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2015-04-23 | — | — | US | disclosed |
| US-9012433-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2858991-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2852590-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-8993619-B2 | Cyclic bridgehead ether DGAT1 inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-104428295-A | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS INC | 2015-03-18 | — | — | CN | disclosed |
| CN-104395309-A | Cyclic bridgehead ether dgat1 inhibitors | NOVARTIS AG | 2015-03-04 | — | — | CN | disclosed |
| US-8962876-B2 | Thermally stable volatile film precursors | WAYNE STATE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140357894-A1 | VISUAL DETECTION OF FLUORIDE IONS | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2014-12-04 | — | — | US | disclosed |
| US-20140349987-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8889868-B2 | CC-1065 analogs and their conjugates | SYNTARGA BV (NL) | 2014-11-18 | — | — | US | disclosed |
| EP-2800745-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORY, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | Phenex Pharmaceuticals AG (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8884060-B2 | Process of preparing chiral diacylhydrazine ligands | INTREXON CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014154612-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8828735-B2 | Visual detection of fluoride ions | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IN) | 2014-09-09 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140221341-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETALACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
| CN-103917528-A | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME | 2014-07-09 | — | — | CN | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2748151-A1 | PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2014091268-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014091268-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697739-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8680293-B2 | Substituted CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2014-03-25 | — | — | US | disclosed |
| US-20140005320-A1 | RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130317031-A1 | Nuclear Transport Modulators And Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2665771-A2 | A RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | Bridgestone Americas Tire Operations, LLC (US) | 2013-11-27 | — | — | EP | disclosed |
| CN-103408454-A | Preparation method of hydrazide compound | UNIV LANGZHOU | 2013-11-27 | — | — | CN | disclosed |
| US-8592590-B2 | Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia | ELI LILLY AND COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2519521-B1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | LILLY CO ELI (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013170068-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170068-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013160873-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2013-10-31 | — | — | WO | disclosed |
| US-20130289058-A1 | CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-10-31 | — | — | US | disclosed |
| EP-2648524-A2 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | Akzo Nobel Chemicals International B.V. (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20130260998-A1 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | WILMINGTON TRUST (LONDON) LIMITED, AS COLLATERAL AGENT (GB) | 2013-10-03 | — | — | US | disclosed |
| CN-103339111-A | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG | 2013-10-02 | — | — | CN | disclosed |
| EP-2640765-A1 | ONE COMPONENT EPOXY RESIN COMPOSITION | Henkel Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130225554-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2013-08-29 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130184275-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2013-07-18 | — | — | US | disclosed |
| US-8481574-B2 | (2Z)-2-(3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene)-1-(5-chloro-2-methoxyphenyl)ethanone; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2013-07-09 | — | — | US | disclosed |
| CN-101679413-B | New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL LAB | 2013-07-03 | — | — | CN | disclosed |
| US-8476191-B2 | Heat-sensitive recording body and method for producing same | Oji Holdings Corporation (JP) | 2013-07-02 | — | — | US | disclosed |
| EP-2606033-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| WO-2013083606-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013079223-A1 | PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORϒ, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2013-06-06 | — | — | WO | disclosed |
| EP-2329956-B1 | HEAT-SENSITIVE RECORDING BODY AND METHOD FOR PRODUCING SAME | OJI PAPER CO (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130102779-A1 | Substituted Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-04-04 | — | — | US | disclosed |
| US-20130082248-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2013-04-04 | — | — | US | disclosed |
| EP-2564446-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2013-03-06 | — | — | EP | disclosed |
| WO-2013028590-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013028590-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-8318706-B2 | Substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8309595-B2 | Hydrazone modulators of cannabinoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2519521-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | Eli Lilly and Company (US) | 2012-11-07 | — | — | EP | disclosed |
| CN-101360704-B | Method for the production of aminoalkane acid amides | BASF SE | 2012-10-17 | — | — | CN | disclosed |
| US-20120252838-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2012-10-04 | — | — | US | disclosed |
| US-8278337-B2 | Substituted pyridines that are JNK inhibitors | MERCK SHARP & DOHME (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120237566-A1 | INHIBITING STOMACH-ACID RELEASE, REDUCING INFLAMMATION AND PREVENTING AND TREATING CANCER: COMPOSITIONS AND METHODS OF USE | Venture Isles, LLC (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012099955-A2 | A RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2012-07-26 | — | — | WO | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| WO-2012076567-A2 | VISCOELASTIC SURFACTANT AS DRIFT CONTROL AGENT IN PESTICIDE FORMULATIONS | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2012-06-14 | — | — | WO | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2012067270-A1 | ONE COMPONENT EPOXY RESIN COMPOSITION | HENKEL JAPAN LTD. (JP) | 2012-05-24 | — | — | WO | disclosed |
| EP-2455367-A1 | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | Paratek Pharmaceuticals, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2452935-A2 | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | Paratek Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2450347-A1 | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections | Paratek Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-8138226-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120058270-A1 | THERMALLY STABLE VOLATILE FILM PRECURSORS | WAYNE STATE UNIVERSITY (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011134013-A1 | ELECTROLUMINESCENT DEVICES BASED ON PHOSPHORESCENT IRIDIUM AND RELATED GROUP VIII METAL MULTICYCLIC COMPOUNDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2011-11-03 | — | — | WO | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| CN-102216277-A | Substituted benzamides as cannabinoid receptor ligands | ABBOTT LAB | 2011-10-12 | — | — | CN | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110177942-A1 | HEAT-SENSITIVE RECORDING BODY AND METHOD FOR PRODUCING SAME | OJI PAPER CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2011082010-A1 | TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160235-A1 | TRIAZOLYL TROPANE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2329956-A1 | HEAT-SENSITIVE RECORDING BODY AND METHOD FOR PRODUCING SAME | Oji Paper Co., Ltd. (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-20110130424-A1 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-7932235-B2 | N-{3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; with deuterium isotop; chemokine (C-C motif) CCR5 receptor antagonist; antiinflammatory agent, viricide; with other active ingredients; HIV, AIDS, multiple sclerosis | CONCERT PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2081893-B1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| EP-2268625-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-7846956-B2 | Malononitrile compound as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20100305072-A1 | Substituted Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2010132871-A1 | THERMALLY STABLE VOLATILE FILM PRECURSORS | WAYNE STATE UNIVERSITY (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-20100197755-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-05 | — | — | US | disclosed |
| US-20100179141-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-07-15 | — | — | US | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | CHU LIN | 2010-06-17 | — | — | US | disclosed |
| US-20100152185-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | CHU LIN | 2010-06-17 | — | — | US | disclosed |
| WO-2010065461-A1 | TRI-PEPTIDE INHIBITORS OF SERINE ELASTASES | ACCUTHERA, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| CN-1922183-B | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD | 2010-05-26 | — | — | CN | disclosed |
| EP-1581532-B1 | PYRAZOLO¬3,4-B PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-7691904-B2 | pH sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2167458-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| CN-101679413-A | New 3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives | ALMIRALL LAB | 2010-03-24 | — | — | CN | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20090312365-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2009-12-17 | — | — | US | disclosed |
| EP-2132178-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-7629467-B2 | 5-lipoxygenase activating protein inhibitors; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
| EP-2109602-A2 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | Paratek Pharmaceuticals, Inc. (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | FORSCHUNGSZENTRUM BORSTEL (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-7589239-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2009-09-15 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7572816-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-7550607-B2 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | AUSPEX PHARMACEUTICAL, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149425-A1 | Malononitrile compound as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20090104633-A1 | Kit for Highly Sensitive Detection Assays | VYZKUMNY USTAV VETERINARNIHO LEKARSTVI (CZ) | 2009-04-23 | — | — | US | disclosed |
| US-20090104633-A1 | Kit for Highly Sensitive Detection Assays | VYZKUMNY USTAV VETERINARNIHO LEKARSTVI (CZ) | 2009-04-23 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| CN-101360704-A | Method for the production of aminoalkane acid amides | BASF SE (DE) | 2009-02-04 | — | — | CN | disclosed |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012227-A1 | HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008153801-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255123-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080248093-A1 | pH sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080221069-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1704143-B1 | MALONONITRILE COMPOUND AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207704-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | THE GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1954669-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948646-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| CN-101223171-A | Pharmacokinetic improved compounds | SURFACE LOGIX INC (US) | 2008-07-16 | — | — | CN | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161264-A1 | TRIAZOLYL TROPANE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008079339-A2 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| EP-1934201-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008063781-A2 | CHEMICAL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008008442-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1742907-A4 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1680409-A4 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070232594-A1 | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| EP-1813603-A1 | AROMATIC AMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICAL USES OF BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7250412-B2 | PH sensitive prodrugs of 2,6-Diisopropylphenol | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007064697-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007058998-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| WO-2007041630-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007028104-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| CN-1922183-A | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| WO-2007022437-A2 | THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND METABOLIC DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1704143-A1 | MALONONITRILE COMPOUND AS PESTICIDES | Sumitomo Chemical Company, Limited (JP) | 2006-09-27 | — | — | EP | disclosed |
| CN-1829689-A | Phenylmethylamine derivatives | ZERIA PHARM CO LTD (JP) | 2006-09-06 | — | — | CN | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
| EP-1083199-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORP (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-1680409-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | Auspex Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20060069132-A1 | Azolecarboxamide herbicides | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-03-30 | — | — | US | disclosed |
| WO-2006030211-A2 | ACYCLIC SULPHONAMIDES | VERNALIS (R & D) LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS INC | 2005-10-20 | — | — | US | disclosed |
| EP-1581532-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005068432-A1 | MALONONITRILE COMPOUND AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005044201-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| CN-1202118-C | Adenosine derivatives | GLAXO GROUP LTD (GB) | 2005-05-18 | — | — | CN | disclosed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004106324-A1 | AZOLECARBOXAMIDE HERBICIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| EP-1380585-B1 | Pyrazolopyridinone as intermediate | PFIZER PROD INC (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1090019-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1447407-A1 | Adenosine derivatives | GLAXO GROUP LIMITED (GB) | 2004-08-18 | — | — | EP | disclosed |
| CN-1161128-C | Angiogenic inhibitory compounds | О | 2004-08-11 | — | — | CN | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1239879-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1239878-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT1 AGONISTS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1380585-A1 | Pyrazolopyridinone | Pfizer Products Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677316-B2 | TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL | SMITHKLINE BEECHAM CORPORATION | 2004-01-13 | — | — | US | disclosed |
| EP-1048667-B1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PROD INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030176642-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2003-09-18 | — | — | US | disclosed |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| US-20030130326-A1 | 1,3,4-oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030096788-A1 | Adenosine derivatives | GLAXO WELLCOME INC. | 2003-05-22 | — | — | US | disclosed |
| US-6548638-B2 | Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. | CORTECH, INC. | 2003-04-15 | — | — | US | disclosed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | disclosed |
| US-6506849-B1 | Natural or synthetic rubber; maleimide compound; and polyaniline, hydrazide and/or amine compound; workability, elasticity | BRIDGESTONE CORPORATION (JP) | 2003-01-14 | — | — | US | disclosed |
| US-20030008842-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-09 | — | — | US | disclosed |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20030004129-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20030004127-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20030004126-A1 | Formulations of adenosine A1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| US-20020198170-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2002-12-26 | — | — | US | disclosed |
| US-6492348-B1 | Adenosine derivatives | SMITHKLINE BEECHAM CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-1093368-A4 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1253144-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-30 | — | — | EP | disclosed |
| EP-1248632-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2002-10-16 | — | — | EP | disclosed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239882-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239883-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239881-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239880-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239878-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| CN-1090612-C | Amine derivatives of oxo-and hydroxy-substituted hydrocarbons | NARHEX LTD (HK) | 2002-09-11 | — | — | CN | disclosed |
| CN-1350525-A | 1,3,4-oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO (JP) | 2002-05-22 | — | — | CN | disclosed |
| US-20020010315-A1 | Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors | GYORKOS ALBERT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1135151-A4 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1089752-A4 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-6326495-B2 | HEATING A MIXTURE OF CAPROLACTONE AND P-METHOXYBENZYLAMINE; CYCLIZATION | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| US-20010039347-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | PFIZER PRODUCTS INC. | 2001-11-08 | — | — | US | disclosed |
| EP-1135151-A1 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1314910-A | Adenosine derivatives | GLAXO GROUP LTD (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-1114822-A2 | Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors | Cortech Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6255453-B1 | INHIBITORS OF HUMAN NEUTOPHIL ELASTASE; TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK, MULTIPLE ORGAN FAILURE, PERIODONTAL DISEASE, GLOMERULONEPHRITIS, CYSTIC FIBROSIS; ANTIARTHRTITIC AGENTS | CORTECH, INC. | 2001-07-03 | — | — | US | disclosed |
| WO-2001045714-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045682-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045684-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045715-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045686-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-1093368-A1 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING $g(a)-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1090019-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| EP-1089752-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | Cortech Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1083199-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORPORATION (JP) | 2001-03-14 | — | — | EP | disclosed |
| EP-1048667-A1 | Process for preparing 8-cyclopentyl-6-ethyl-3-(substituted)-5,8-dihydro-4H-1,2,3A,7,8-pentaaza-as-indacenes and intermediates useful therein | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6100238-A | USEFUL AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE (HNE) FOR THE TREATMENT OF HNE-MEDIATED PROCESSES IMPLICATED IN CONDITIONS SUCH AS ADULT RESPIRATORY DISTRESS SYNDROME, SEPTIC SHOCK AND MULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000032216-A1 | PEPTOID AND NONPEPTOID CONTAINING ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| CN-1052717-C | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 2000-05-24 | — | — | CN | disclosed |
| CN-1052717-C | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 2000-05-24 | — | — | CN | disclosed |
| CN-1052717-C | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 2000-05-24 | — | — | CN | disclosed |
| US-6017848-A | USED IN FACSIMILES AND CALULATORS, POINT OF SALES LABELS | OJI PAPER CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| WO-1999067262-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| US-6001813-A | Val-pro containing α-keto oxadiazoles as serine protease inhibitors | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-6001814-A | TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME, SEPSISMULTIPLE ORGAN FAILURE | CORTECH INC. (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999062514-A1 | INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING α-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062538-A1 | ALPHA-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS | CORTECH INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0899126-A1 | Heat sensitive recording material | OJI PAPER CO., LTD. (JP) | 1999-03-03 | — | — | EP | disclosed |
| EP-0653419-B1 | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1997-09-17 | — | — | EP | disclosed |
| EP-0653419-B1 | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1997-09-17 | — | — | EP | disclosed |
| CN-1108242-A | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1995-09-13 | — | — | CN | disclosed |
| CN-1108242-A | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1995-09-13 | — | — | CN | disclosed |
| CN-1108242-A | Preparation of pivaloyl hydrazide | SHELL INT RESEARCH (NL) | 1995-09-13 | — | — | CN | disclosed |
| JP-H07215924-A | PRODUCTION OF PIVALOYL HYDRAZIDE | SHELL INTERNATL RES MAATSCHAPPIJ BV | 1995-08-15 | — | — | JP | disclosed |
| JP-H07215924-A | PRODUCTION OF PIVALOYL HYDRAZIDE | SHELL INTERNATL RES MAATSCHAPPIJ BV | 1995-08-15 | — | — | JP | disclosed |
| US-5433896-A | FLUORESCENT | MOLECULAR PROBES, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0653419-A1 | Preparation of pivaloyl hydrazide | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-05-17 | — | — | EP | disclosed |
| EP-0653419-A1 | Preparation of pivaloyl hydrazide | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-05-17 | — | — | EP | disclosed |
| EP-0653419-A1 | Preparation of pivaloyl hydrazide | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-05-17 | — | — | EP | disclosed |
| CN-1100090-A | amine derivatives of oxo-and hydroxy-substituted hydrocarbons | NARHEX LTD (HK) | 1995-03-15 | — | — | CN | disclosed |
| US-5237099-A | Insecticidal substituted and unsubstituted benzoic acid 1-alkyl, 2-alkyl and 2-cycloalkylhydrazides | AMERICAN CYANAMID COMPANY (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0228564-B1 | NOVEL INSECTICIDAL DIACYLHYDRAZINE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1992-01-29 | — | — | EP | disclosed |
| EP-0232075-B1 | INSECTICIDAL N'-SUBSTITUTED-N-ALKYLCARBONYL-N'-ACYL HYDRAZINES | ROHM AND HAAS COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4904724-A | FREE RADICAL POLYMERIZATION OF CI-C20-ALKYL(METH)ACRYLATE AND UNSATURATED MONOMERS | BASF AKTIENGESELLSCHAFT (DE) | 1990-02-27 | — | — | US | disclosed |
| US-4814349-A | Insecticidal substituted and unsubstituted benzoic acid 1-alkyl, 2 alkyl and 2-cycloalkylhydrazides | AMERICAN CYANAMID COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0303286-A1 | 2-Oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E.R. Squibb & Sons, Inc. (US) | 1989-02-15 | — | — | EP | disclosed |
| CN-88102858-A | Process for preparing hydrazine derivatives useful as antihypertensive agents | — | 1988-12-14 | — | — | CN | disclosed |
| US-4777252-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1988-10-11 | — | — | US | disclosed |
| EP-0232075-A1 | Insecticidal N'-substituted-N-alkylcarbonyl-N'-acyl hydrazines | ROHM AND HAAS COMPANY (US) | 1987-08-12 | — | — | EP | disclosed |
| EP-0228564-A2 | Novel insecticidal diacylhydrazine compounds | AMERICAN CYANAMID COMPANY (US) | 1987-07-15 | — | — | EP | disclosed |
| US-4560752-A | Phosphinates or phosphonates useful for control of weeds | ZOECON CORPORATION (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0111442-A1 | N-2-heterocyclyl-phenylsulfonyl-N'-pyrimidinyl and like triazinyl urea | CIBA-GEIGY AG (CH) | 1984-06-20 | — | — | EP | disclosed |
| US-4282169-A | FUNGICIDES | OLIN CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4073792-A | 5-Aryl-pyrido-(b-6,7)-1,4-diazaepine with an additional fused heterocyclic ring | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1978-02-14 | — | — | US | disclosed |
| US-3935315-A | Insecticidal and acaricidal phenylhydrazone derivatives | RHONE-POULENC S.A. (FR) | 1976-01-27 | — | — | US | disclosed |
| US-3935315-A | Insecticidal and acaricidal phenylhydrazone derivatives | RHONE-POULENC S.A. (FR) | 1976-01-27 | — | — | US | disclosed |